Open Medicine EU

Archives for Competition

It’s Not All Bad News

In telling the Parliament on Wednesday that the units on medicines and pharmaceutical products will stay with DG Sanco Mr Juncker added “..I agree with you that medicines are not goods like any other”. I couldn’t have put it better myself. This is good news and thanks to those who worked to achieve it, especially… » read more

Posted by Jim Murray

Citing Regulation (EC) 1049/2001, I asked last month for access to the following documents: ‘All communications in any form, and notes or records in any form of communications between DG Enterprise and any pharmaceutical Industry association concerning the policy, draft policy or decision making process of the European Medicines Agency on the issue of access… » read more

Posted by Jim Murray

Joint letters with like-minded organisations are never easy to write, even among friends. Each organisation wants to add its own nuance.Different organisations may have different rules for sign-off on final drafts, and amendments can ping-pong from one to the other. I’ve been there. Sometimes, however, an issue is so important and clear that a joint… » read more

Posted by Jim Murray

Some years ago, DG Sanco, the health directorate for public health, took over the lead role for medicines and medical devices from DG Enterprise the industry DG, which was responsible for promoting industry, including the pharmaceutical industry. The change was a good one, enabling a clearer focus within the Commission on medicines as an essential… » read more

Posted by Jim Murray

As I mentioned previously the Ombudsman had, on her own initiative, looked into the apparent change of policy on transparency in the European Medicines Agency. She has now published on her website copies of correspondence between the Commission and the EMA on the subject. For those of us who can sometimes get excited about such… » read more

Posted by Jim Murray

These are my notes for a speech I made today in the European Parliament on the proposal for a directive on trade secrets. 1 I will not say anything here about the proposal itself in terms of its principal objective but will talk about some possible indirect effects. – in relation to journalists, whistleblowers and… » read more

Posted by Jim Murray

The issue of open access to data from clinical trials is moving to the fore. Four regulators, from the British, Dutch, French and European medicines agencies, have responded to an earlier paper arguing for open access in PLoS Medicine. This is high level stuff. The authors reject the notion that clinical trial results could be… » read more

Posted by Jim Murray

I covered previously the written question from Nessa Childers MEP arising from the extensive bribery of surgeons in Greece some years ago – see my earlier post here. The Commission has now given an answer, and it is bizarre. While the bribery was going on, certain orthopedic devices were twice as expensive in Greece compared… » read more

Posted by Jim Murray

MEDICAL DEVICES

In some previous posts, here and here, I described how (prior to 2006) orthopaedic surgeons in Greece were paid to prescribe particular medical devices such as knee and hip replacements. The bribery was first uncovered under the Foreign Corrupt Practices Act in the US. This was followed by action by the UK Serious Fraud Office… » read more

Posted by Jim Murray